Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q6)Jun 30, 2025 | (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 4.20%19.65B | 20.87%38.29B | 32.09%18.86B | -4.57%31.68B | -15.87%14.28B | -11.47%33.2B | -14.43%16.97B | -1.33%37.5B | 5.14%19.83B | 0.40%38B |
| Operating income | 4.20%19.65B | 20.87%38.29B | 32.09%18.86B | -4.57%31.68B | -15.87%14.28B | -11.47%33.2B | -14.43%16.97B | -1.33%37.5B | 5.14%19.83B | 0.40%38B |
| Cost of sales | -0.92%-15.76B | -15.49%-31.29B | -28.53%-15.61B | -1.88%-27.09B | 9.68%-12.15B | 7.54%-26.59B | 9.66%-13.45B | 1.85%-28.76B | 1.98%-14.89B | 2.64%-29.3B |
| Operating expenses | -0.92%-15.76B | -15.49%-31.29B | -28.53%-15.61B | -1.88%-27.09B | 9.68%-12.15B | 7.54%-26.59B | 9.66%-13.45B | 1.85%-28.76B | 1.98%-14.89B | 2.64%-29.3B |
| Gross profit | 19.96%3.89B | 52.62%7.01B | 52.37%3.25B | -30.50%4.59B | -39.51%2.13B | -24.40%6.6B | -28.79%3.52B | 0.44%8.74B | 34.55%4.95B | 12.22%8.7B |
| Selling expenses | 18.50%-184.24M | -5.84%-439.33M | 5.84%-226.07M | -17.66%-415.1M | -46.91%-240.09M | -28.70%-352.79M | -5.10%-163.43M | 12.56%-274.11M | -14.34%-155.5M | -12.51%-313.48M |
| Administrative expenses | -5.21%-592.79M | -38.55%-1.4B | -23.04%-563.46M | -8.76%-1.01B | -4.56%-457.94M | -22.57%-928.58M | -16.11%-437.99M | -5.43%-757.59M | -13.13%-377.23M | -10.48%-718.57M |
| Research and development expenses | -11.25%-1.63B | -13.93%-2.92B | -21.88%-1.47B | 8.45%-2.57B | 17.94%-1.2B | -6.10%-2.8B | -11.16%-1.47B | -5.73%-2.64B | -23.67%-1.32B | -13.11%-2.5B |
| Impairment and provision | 79.65%-5.49M | 99.56%-99K | -379.94%-26.96M | -111.08%-22.31M | 28.95%-5.62M | -103.98%-10.57M | 45.45%-7.91M | -142.41%-5.18M | -97.76%-14.49M | 212.10%12.22M |
| -Other impairment is provision | 79.65%-5.49M | 99.56%-99K | -379.94%-26.96M | -111.08%-22.31M | 28.95%-5.62M | -103.98%-10.57M | 45.45%-7.91M | -142.41%-5.18M | -97.76%-14.49M | 212.10%12.22M |
| Special items of operating profit | -4.66%538.49M | 6.05%1.28B | -1.18%564.82M | 139.59%1.21B | 61.99%571.58M | -36.09%504.25M | 32.17%352.85M | 13.10%789.01M | 132.90%266.97M | 240.50%697.65M |
| Operating profit | 32.13%2.02B | 97.48%3.52B | 92.32%1.53B | -40.78%1.78B | -55.85%793.71M | -48.45%3.01B | -46.26%1.8B | -0.52%5.85B | 48.94%3.35B | 22.27%5.88B |
| Financing cost | 10.59%-243.81M | -11.18%-499.38M | -18.06%-272.69M | -53.33%-449.15M | -101.02%-230.97M | -27.22%-292.94M | 1.30%-114.9M | 1.49%-230.25M | 5.00%-116.42M | 6.67%-233.74M |
| Share of profits of associates | 1,926.75%92.25M | 425.76%118.38M | -117.33%-5.05M | 475.52%22.52M | 2,951.52%29.14M | -131.55%-6M | 4,675.00%955K | 94,935.00%19.01M | 110.70%20K | 100.36%20K |
| Earning before tax | 49.38%1.87B | 131.46%3.14B | 110.97%1.25B | -49.98%1.36B | -64.85%591.88M | -51.82%2.71B | -47.85%1.68B | -0.14%5.63B | 52.06%3.23B | 24.01%5.64B |
| Tax | -2.84%-141.07M | -76.35%-366.51M | -3.54%-137.17M | 13.70%-207.83M | 56.55%-132.49M | 58.40%-240.83M | 41.63%-304.92M | 17.60%-578.97M | -50.40%-522.34M | -32.33%-702.63M |
| After-tax profit from continuing operations | 55.12%1.72B | 141.41%2.78B | 141.96%1.11B | -53.51%1.15B | -66.68%459.39M | -51.06%2.47B | -49.06%1.38B | 2.34%5.06B | 52.39%2.71B | 22.91%4.94B |
| Earning after tax | 55.12%1.72B | 141.41%2.78B | 141.96%1.11B | -53.51%1.15B | -66.68%459.39M | -51.06%2.47B | -49.06%1.38B | 2.34%5.06B | 52.39%2.71B | 22.91%4.94B |
| Minority profit | 139.99%78.05M | 52.95%77.87M | 43.41%32.52M | -23.28%50.91M | 8.31%22.68M | -2.29%66.35M | 12.26%20.94M | -0.81%67.91M | -31.19%18.65M | 143.83%68.46M |
| Profit attributable to shareholders | 52.56%1.65B | 145.51%2.7B | 147.07%1.08B | -54.34%1.1B | -67.84%436.71M | -51.73%2.41B | -49.48%1.36B | 2.39%4.99B | 53.68%2.69B | 22.06%4.87B |
| Basic earnings per share | 53.03%1.5156 | 146.39%2.4816 | 147.66%0.9904 | -54.27%1.0072 | -67.78%0.3999 | -51.75%2.2026 | -49.52%1.2413 | 2.41%4.5652 | 53.85%2.4592 | 22.20%4.4578 |
| Diluted earnings per share | 52.47%1.5096 | 146.33%2.4788 | 147.83%0.9901 | -54.29%1.0063 | -67.79%0.3995 | -51.71%2.2015 | -49.49%1.2403 | 2.42%4.5593 | 53.83%2.4554 | 22.23%4.4514 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
| Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
| Auditor | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.